Cargando…

Analysis of in vivo turnover of tau in a mouse model of tauopathy

BACKGROUND: Intracellular accumulation of tau as neurofibrillary tangles (NFTs) is the hallmark of Alzheimer’s disease (AD) as well as in other tauopathies. Tau is present not only in the cytoplasm but also in the extracellular space such as cerebrospinal fluid (CSF) and brain interstitial fluid (IS...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamada, Kaoru, Patel, Tirth K., Hochgräfe, Katja, Mahan, Thomas E., Jiang, Hong, Stewart, Floy R., Mandelkow, Eva-Maria, Holtzman, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621881/
https://www.ncbi.nlm.nih.gov/pubmed/26502977
http://dx.doi.org/10.1186/s13024-015-0052-5
_version_ 1782397511115210752
author Yamada, Kaoru
Patel, Tirth K.
Hochgräfe, Katja
Mahan, Thomas E.
Jiang, Hong
Stewart, Floy R.
Mandelkow, Eva-Maria
Holtzman, David M.
author_facet Yamada, Kaoru
Patel, Tirth K.
Hochgräfe, Katja
Mahan, Thomas E.
Jiang, Hong
Stewart, Floy R.
Mandelkow, Eva-Maria
Holtzman, David M.
author_sort Yamada, Kaoru
collection PubMed
description BACKGROUND: Intracellular accumulation of tau as neurofibrillary tangles (NFTs) is the hallmark of Alzheimer’s disease (AD) as well as in other tauopathies. Tau is present not only in the cytoplasm but also in the extracellular space such as cerebrospinal fluid (CSF) and brain interstitial fluid (ISF). Although clearance is one critical parameter leading to such intracellular/extracellular tau accumulation, in vivo turnover of tau has not been well characterized. The current study has attempted to precisely determine in vivo turnover rates of tau utilizing tet-off regulatable mice. In particular, we assessed intracellular tau and extracellular tau, soluble tau, insoluble tau and phosphorylated tau at certain sites utilizing a combination of in vivo microdialysis, biochemical analysis and specific ELISAs recognizing each species. To examine the effect of a tauopathy-associated mutation on tau clearance, half-lives of various tau species were compared between the mice with a FTDP-17 mutation that induces β-sheet formation, ΔK280 mutation (pro-aggregant mice) and control mice with additional β-sheet breaking mutations (anti-aggregant mice). RESULTS: Here we report that tau is metabolized at much slower turnover rates in vivo than in cell culture. We found that insoluble tau in pro-aggregant mice had a significantly slower half-life (t(1/2) = ~34.2 days) than soluble tau (t(1/2) = ~9.7 days). In contrast, soluble tau phosphorylated in the proline rich region was cleared faster than total soluble tau. When comparing pro-aggregant mice to anti-agregant mice, turnover rates of soluble tau species were not significantly different. CONCLUSIONS: The current study provides a comprehensive description of in vivo turnover of various tau species present in mice that express human tau. The turnover rate of soluble tau was not significantly altered between pro-aggregant mice and anti-aggregant mice. This suggests that altered conformation by ΔK280 does not have a major impact on clearance pathways for soluble tau. In contrast, different tau species displayed different half-lives. Turnover was significantly delayed for insoluble tau whereas it was accelerated for soluble tau phosphorylated in the proline rich region. These differences in susceptibilities to clearance suggest that aggregation and phosphorylation influences tau clearance which may be important in tau pathogenesis.
format Online
Article
Text
id pubmed-4621881
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46218812015-10-28 Analysis of in vivo turnover of tau in a mouse model of tauopathy Yamada, Kaoru Patel, Tirth K. Hochgräfe, Katja Mahan, Thomas E. Jiang, Hong Stewart, Floy R. Mandelkow, Eva-Maria Holtzman, David M. Mol Neurodegener Research Article BACKGROUND: Intracellular accumulation of tau as neurofibrillary tangles (NFTs) is the hallmark of Alzheimer’s disease (AD) as well as in other tauopathies. Tau is present not only in the cytoplasm but also in the extracellular space such as cerebrospinal fluid (CSF) and brain interstitial fluid (ISF). Although clearance is one critical parameter leading to such intracellular/extracellular tau accumulation, in vivo turnover of tau has not been well characterized. The current study has attempted to precisely determine in vivo turnover rates of tau utilizing tet-off regulatable mice. In particular, we assessed intracellular tau and extracellular tau, soluble tau, insoluble tau and phosphorylated tau at certain sites utilizing a combination of in vivo microdialysis, biochemical analysis and specific ELISAs recognizing each species. To examine the effect of a tauopathy-associated mutation on tau clearance, half-lives of various tau species were compared between the mice with a FTDP-17 mutation that induces β-sheet formation, ΔK280 mutation (pro-aggregant mice) and control mice with additional β-sheet breaking mutations (anti-aggregant mice). RESULTS: Here we report that tau is metabolized at much slower turnover rates in vivo than in cell culture. We found that insoluble tau in pro-aggregant mice had a significantly slower half-life (t(1/2) = ~34.2 days) than soluble tau (t(1/2) = ~9.7 days). In contrast, soluble tau phosphorylated in the proline rich region was cleared faster than total soluble tau. When comparing pro-aggregant mice to anti-agregant mice, turnover rates of soluble tau species were not significantly different. CONCLUSIONS: The current study provides a comprehensive description of in vivo turnover of various tau species present in mice that express human tau. The turnover rate of soluble tau was not significantly altered between pro-aggregant mice and anti-aggregant mice. This suggests that altered conformation by ΔK280 does not have a major impact on clearance pathways for soluble tau. In contrast, different tau species displayed different half-lives. Turnover was significantly delayed for insoluble tau whereas it was accelerated for soluble tau phosphorylated in the proline rich region. These differences in susceptibilities to clearance suggest that aggregation and phosphorylation influences tau clearance which may be important in tau pathogenesis. BioMed Central 2015-10-26 /pmc/articles/PMC4621881/ /pubmed/26502977 http://dx.doi.org/10.1186/s13024-015-0052-5 Text en © Yamada et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Yamada, Kaoru
Patel, Tirth K.
Hochgräfe, Katja
Mahan, Thomas E.
Jiang, Hong
Stewart, Floy R.
Mandelkow, Eva-Maria
Holtzman, David M.
Analysis of in vivo turnover of tau in a mouse model of tauopathy
title Analysis of in vivo turnover of tau in a mouse model of tauopathy
title_full Analysis of in vivo turnover of tau in a mouse model of tauopathy
title_fullStr Analysis of in vivo turnover of tau in a mouse model of tauopathy
title_full_unstemmed Analysis of in vivo turnover of tau in a mouse model of tauopathy
title_short Analysis of in vivo turnover of tau in a mouse model of tauopathy
title_sort analysis of in vivo turnover of tau in a mouse model of tauopathy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621881/
https://www.ncbi.nlm.nih.gov/pubmed/26502977
http://dx.doi.org/10.1186/s13024-015-0052-5
work_keys_str_mv AT yamadakaoru analysisofinvivoturnoveroftauinamousemodeloftauopathy
AT pateltirthk analysisofinvivoturnoveroftauinamousemodeloftauopathy
AT hochgrafekatja analysisofinvivoturnoveroftauinamousemodeloftauopathy
AT mahanthomase analysisofinvivoturnoveroftauinamousemodeloftauopathy
AT jianghong analysisofinvivoturnoveroftauinamousemodeloftauopathy
AT stewartfloyr analysisofinvivoturnoveroftauinamousemodeloftauopathy
AT mandelkowevamaria analysisofinvivoturnoveroftauinamousemodeloftauopathy
AT holtzmandavidm analysisofinvivoturnoveroftauinamousemodeloftauopathy